[1] Chen W, Zheng R, Baade P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016 ,66(2):115-132. [2] 《原发性肝癌诊疗指南(2024年版)》编写专家委员会,周俭.原发性肝癌诊疗指南(2024年版)[J].中国临床医学,2024,31(2):277-334. [3] 中华医学会肝病学分会,中华医学会感染病学分会, 丙型肝炎防治指南(2022年版)[J].中华传染病杂志, 2023,41(1):29-46. [4] Jia Y, Zou X, Yue W, et al. The distribution of hepatitis C viral genotypes shifted among chronic hepatitis C patients in Yunnan, China, between 2008-2018[J]. Front Cell Infect Microbiol, 2023,13:1092936. [5] 王晓忠,魏来.中国慢性丙型肝炎基因3型患者的现状、治疗和展望[J].中华肝脏病杂志,2020,28(10):824-826. [6] Jain D, Chaudhary P, Varshney N, et al. Tobacco smoking and liver cancer risk: potential avenues for carcinogenesis[J]. J Oncol, 2021 ,10,2021:5905357. [7] Kanwal F, Kramer J R, Asch S M, et al. Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents[J]. Hepatology, 2020 ,71(1):44-55. [8] 刘记平,张治涛.血氨水平与凝血指标变化对肝硬化合并肝癌的诊断意义[J].实用医药杂志,2018,35(1):29-30. [9] Wang X P, Mao M J, He Z L, et al. A retrospective discussion of the prognostic value of combining protHRombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma[J]. J Cancer, 2017,8(11): 2079-2087. [10] Schweitzer N, Weber T, Kirstein M M, et al. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis[J]. J Cancer Res Clin Oncol, 2017. 143(7):1347-1355. [11] Wang H S, Ge X X, Li Q P, et al. Clinical significance of ProtHRombin time in cholangiocarcinoma patients with surgeries[J]. Can J Gastroenterol Hepatol,2019, 2019: 3413969. [12] Hsu C Y, Lee Y H, Huang Y H,et al. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy.[J] Hepatol Int, 2013,7(1): 188-198. [13] Liao J I, Ho S Y, Liu P H, et al. Prognostic prediction for patients with hepatocellular carcinoma and ascites: role of albumin-bilirubin (AlbI) grade and easy (EZ)-AlbI grade[J]. Cancers (Basel), 2023, 15(3):753. [14] Giannini E G, Risso D, Testa R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma[J]. Clin Gastroenterol Hepatol, 2006,4(11): 1378-1384. [15] Lim J, Kim H I, Kim E, et al. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study[J]. BMC Cancer, 2021,21(1): 11. [16] Vergara V, Muratore A, Bouzari H, et al. Spontaneous rupture of hepatocelluar carcinoma: surgical resection and long-term survival[J]. Eur J Surg Oncol, 2000, 26(8): 770-772. [17] Kirikoshi H, Saito S, Yoneda M,et al. Outcomes and factors influencing survival in cirrhotic cases with spontaneous rupture of hepatocellular carcinoma: a multicenter study[J]. BMC Gastroenterol, 2009,9: 29. [18] 尹袁英,刘伟,张铭光.影响肝癌破裂出血患者预后生存期的危险因素分析[J].实用癌症杂志,2020,35(9):1508-1511. |